Patents by Inventor Douglas John Bartels

Douglas John Bartels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Influenza A virus variants
    Patent number: 10801076
    Abstract: The present invention relates to influenza A virus variants, particularly variants that are resistant to a polymerase inhibitors. Also provided are methods and compositions related to the influenza A virus variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: October 13, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Joshua Robert Leeman, Randal Byrn, Hamilton Barlow Bennett, Douglas John Bartels
  • Influenza A virus variants
    Patent number: 10801077
    Abstract: The present invention relates to influenza A virus variants, particularly variants that are resistant to a polymerase inhibitors. Also provided are methods and compositions related to the influenza A virus variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: October 13, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Joshua Robert Leeman, Randal Byrn, Hamilton Barlow Bennett, Douglas John Bartels
  • INFLUENZA A VIRUS VARIANTS
    Publication number: 20170204479
    Abstract: The present invention relates to influenza A virus variants, particularly variants that are resistant to a polymerase inhibitors. Also provided are methods and compositions related to the influenza A virus variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
    Type: Application
    Filed: March 31, 2017
    Publication date: July 20, 2017
    Inventors: Joshua Robert Leeman, Randal Byrn, Hamilton Barlow Bennett, Douglas John Bartels
  • INFLUENZA A VIRUS VARIANTS
    Publication number: 20170204478
    Abstract: The present invention relates to influenza A virus variants, particularly variants that are resistant to a polymerase inhibitors. Also provided are methods and compositions related to the influenza A virus variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
    Type: Application
    Filed: March 31, 2017
    Publication date: July 20, 2017
    Inventors: Joshua Robert Leeman, Randal Byrn, Hamilton Barlow Bennett, Douglas John Bartels
  • METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS
    Publication number: 20140199684
    Abstract: A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11.
    Type: Application
    Filed: January 28, 2014
    Publication date: July 17, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ann Dak-Yee Kwong, James Daniel Frantz, Douglas John Bartels, Chao Lin, Benjamin Shames, Sheila Seepersaud, Judith A. Lippke, Tara Lynn Kieffer, Yi Zhou, Eileen Z. Zhang, James C. Sullivan
  • Methods for amplifying hepatitis C virus nucleic acids
    Patent number: 8679740
    Abstract: A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: March 25, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ann Dak-Yee Kwong, James Daniel Frantz, Douglas John Bartels, Chao Lin, Benjamin Shames, Sheila Seepersaud, Judith A. Lippke, Tara Lynn Kieffer, Yi Zhou, Eileen Z. Zhang, James C. Sullivan
  • ANALYSIS OF HCV GENOTYPES
    Publication number: 20140050697
    Abstract: A method for predicting response of a patient infected with HCV-1a to interferon treatment.
    Type: Application
    Filed: June 6, 2013
    Publication date: February 20, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Douglas John Bartels, Ann Dak-Yee Kwong, Tara Lynn Kieffer
  • METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS
    Publication number: 20120129155
    Abstract: A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11.
    Type: Application
    Filed: July 20, 2011
    Publication date: May 24, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Ann Dak-Yee Kwong, James Daniel Frantz, Douglas John Bartels, Chao Lin, Benjamin Shames, Sheila Seepersaud, Judith A. Lippke, Tara Lynn Kieffer, Yi Zhou, Eileen Z. Zhang, James C. Sullivan
  • ANALYSIS OF HCV GENOTYPES
    Publication number: 20120088904
    Abstract: A method for predicting response of a patient infected with HCV-1a to interferon treatment
    Type: Application
    Filed: February 28, 2011
    Publication date: April 12, 2012
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Douglas John Bartels, Ann Dak-Yee Kwong, Tara Lynn Kieffer